A Dose-Finding Study of MM-120 for the Treatment of Anxiety Symptoms

This is a Phase II, multi-centre, randomized, double-blind, parallel-group, dose-finding study to assess the effect of four doses of MM-120 (25, 50, 100 or 200 μg LSD freebase-equivalent) for the treatment of anxiety symptoms in subjects diagnosed with generalized anxiety disorder (GAD).

Topic Anxiety
Compound LSD
Country United States of America
Visit trial
Status Recruiting
Results Published
Start date 27 June 2022
End date 30 November 2023
Chance of happening 89%
Phase Phase II
Design Blinded
Type Interventional
Generation Second
Participants 200
Sex All
Age 18- 74
Therapy No

Trial Details

The study will enroll approximately 200 male and female subjects 18 years to < 75 years of age who meet DSM-5 criteria for GAD and have a minimum HAM-A Total Score of 20. Subjects on contraindicated concomitant medications, supplements or other therapeutics at Screening (Visit 1) will undergo a medication taper prior to advancing to Baseline (Visit 2).

NCT Number NCT05407064

Sponsors & Collaborators

MindMed
MindMed is one of the largest companies in the psychedelics space and is developing various psychedelics for mental health disorders.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.